Inflammatory biomarkers for non-metastatic kidney cancer

This study looked at inflammatory biomarkers in the blood for the diagnosis of non-metastatic renal cell carcinoma (RCC).  Inflammation is known to be associated with cancer, and there have been a number of studies that have looked at the relationship between cancer and inflammatory biomarkers. Inflammatory biomarkers such as the neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, lymphocyte/monocyte […]

read more

ASCO 2020: Subtypes of kidney cancer differ in sites of metastases

A paper presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program last weekend showed that histologic subtypes of metastatic renal cell carcinoma (RCC) differ in the location of their metastases. For example, lung, adrenal, brain, and pancreatic metastases occur more frequently with clear cell RCC than with papillary RCC or chromophobe […]

read more

A potential biomarker for survival for non-metastatic kidney cancer

A recent study published in the journal International Urology and Nephrology this month evaluates mean platelet volume-to-lymphocyte ratio (MPVLR) as a biomarker for survival in patients undergoing nephrectomy for non-metastatic clear cell renal cell carcinoma (ccRCC). In the study, 344 patients with proven ccRCC that has not spread (non-metastatic) were treated with radical or partial […]

read more

The most complete catalogue of clear cell renal cell carcinoma (ccRCC)

Researchers at the University of Texas (UT) Southwestern Medical Center have developed what could be the most complete catalogue of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer. This cancer is very diverse in character (heterogenous) and there is high variability in tumours. This heterogeneity makes is difficult to diagnose […]

read more

Panobinostat plus everolimus not effective in metastatic kidney cancer

A recent phase I clinical trial assessed the combination of everolimus (an mTOR inhibitor) with panobinostat (a histone deacetylase inhibitor) in 21 patients with clear-cell metastatic renal cell carcinoma (RCC) who had disease progression within 6 months of stopping treatment with VEGFR TKIs. Median progression-free survival was 4.1 months. Anaemia and thrombocytopenia were the most […]

read more

PD-L1 can be used to predict the likely course of kidney cancer

A recently published study evaluated the role of programmed-death receptor ligand (PD-L1) as an indicator of the likely course (prognosis) of clear cell renal cell carcinoma (RCC). A total of 738 patients were included in the study and followed for around 34 months. The presence of PD-L1 and PD-1 receptors in the tumour cells was […]

read more

MicroRNA as a marker for kidney cancer

A recent study has provided evidence that a group of microRNAs, called the miRNA-200 family, can be used to predict the likely course of clear cell renal cell carcinoma (RCC). MicroRNAs (miRNAs) are small pieces of RNA (nucleic acid that is found in all living cells) that act as messengers to regulate the synthesis of […]

read more

Lenvatinib plus pembrolizumab combination shows promise in metastatic kidney cancer

Interim results from an ongoing clinical trial of lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma (RCC) who have already received an immune checkpoint inhibitor. The trial included up to 360 patients with various cancers, of which 33 patients had metastatic clear cell RCC. The patients took a […]

read more

New subtypes of kidney cancer identified

Using advanced proteogenomic technologies to look at genetic makeup and proteins, researchers from the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) in America have identified four subtypes of clear cell renal cell carcinoma (RCC). The researchers found that almost all of the clear cell RCC tumour samples in the study lacked chromosome 3p. […]

read more

ASCO 2019: First-line pembrolizumab for advanced kidney cancer

Two presentations on the results of the KEYNOTE-427 clinical trial were given at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago this week. KEYNOTE-427 is an open-label, multicentre, global phase 2 study evaluating the efficacy and safety of pembrolizumab as a first-line treatment for patients with advanced or metastatic renal cell […]

read more
Showing 1 to 10 of 16 results
  TOP